See more : Ackermans & Van Haaren NV (AVHNY) Income Statement Analysis – Financial Results
Complete financial analysis of Enochian Biosciences, Inc. (ENOB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enochian Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SHL Telemedicine Ltd. (SHLT) Income Statement Analysis – Financial Results
- Bicicletas Monark S.A. (BMKS3.SA) Income Statement Analysis – Financial Results
- Nanfang Black Sesame Group Co., Ltd. (000716.SZ) Income Statement Analysis – Financial Results
- Neon Bloom, Inc. (NBCO) Income Statement Analysis – Financial Results
- STWC Holdings, Inc. (STWC) Income Statement Analysis – Financial Results
Enochian Biosciences, Inc. (ENOB)
About Enochian Biosciences, Inc.
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.77K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 121.86K | 113.50K | 123.59K | 391.42K | 366.27K | 71.71K | 18.48K | 14.53K | 32.67K | 314.64K | 0.00 | 0.00 |
| Gross Profit | -121.86K | -113.50K | -123.59K | -391.42K | -366.27K | -71.71K | -18.48K | -14.53K | 10.10K | -314.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.62% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.71M | 4.17M | 8.37M | 15.72M | 4.69M | 2.50M | 616.96K | 62.76K | 804.19K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.17M | 15.32M | 14.33M | 7.56M | 7.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 383.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.56M | 15.32M | 14.33M | 7.56M | 7.12M | 8.42M | 2.60M | 2.32M | 1.33M | 2.11M | 37.09K | 29.95K |
| Other Expenses | 54.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.92M | 3.22M | 2.39M | 2.13M | 2.11M | 37.09K | 29.95K |
| Cost & Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.99M | 3.24M | 2.40M | 2.16M | 2.43M | 37.09K | 29.95K |
| Interest Income | 0.00 | 0.00 | 122.04K | 13.18K | 50.30K | 73.49K | 45.82K | 0.00 | 0.00 | 5.94K | 0.00 | 0.00 |
| Interest Expense | 1.01M | 706.96K | 372.84K | 379.61K | 104.28K | 43.00 | 143.26K | 26.26K | 2.36K | 84.55K | 497.00 | 0.00 |
| Depreciation & Amortization | 121.86K | 113.50K | 123.59K | 123.53K | 366.27K | 71.71K | 18.48K | 14.53K | 27.40K | 45.20K | 0.00 | 0.00 |
| EBITDA | -79.52M | -19.48M | -22.70M | -23.28M | -11.51M | -17.94M | -5.31M | -2.39M | -2.17M | -2.42M | -37.09K | -29.95K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,894.99% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.64M | -38.56M | -116.08M | -23.40M | -11.92M | -10.99M | -3.24M | -2.40M | -2.12M | -2.43M | -37.09K | -29.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,959.04% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 989.12K | -1.13M | 2.65M | -3.45M | 507.41K | -7.03M | -3.19M | 192.72K | -77.10K | -119.20K | -497.00 | 0.00 |
| Income Before Tax | -80.65M | -39.68M | -113.43M | -26.85M | -11.42M | -18.02M | -6.42M | -2.21M | -2.20M | -2.55M | -37.59K | -29.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,139.30% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 706.96K | 34.00 | -125.28K | 104.28K | 1.00 | -111.72K | -64.88K | -462.79K | -177.54K | 0.00 | 0.00 |
| Net Income | -80.65M | -39.68M | -113.43M | -26.72M | -11.42M | -18.02M | -6.31M | -2.14M | -1.74M | -2.37M | -37.59K | -29.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,057.24% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| EPS Diluted | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
| Weighted Avg Shares Out (Dil) | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
Company encouraged by clear path following review of FDA's CBER written comments Company encouraged by clear path following review of FDA's CBER written comments
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a...
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the...
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach
Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug)...
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences...
Enochian Biosciences: A Follow Through For An HIV Cure
Enochian Biosciences: A Follow Through For An HIV Cure
Why Enochian BioSciences Was a Winner on Monday
The company scores an exclusive license for new potential coronavirus treatment technology.
Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology
Enochian BioSciences Inc (NASDAQ: ENOB) has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza. The technology is delivered by a nanoparticle, allowing it to either rapidly...
Source: https://incomestatements.info
Category: Stock Reports